INVA-8002 is under clinical development by Invea Therapeutics and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how INVA-8002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
INVA-8002 is under development for the treatment of ulcerative colitis in combination with anti-TNF regimen and irritable bowel syndrome (IBS). It is a new chemical entity. It is being developed based on artificial intelligence AI-powered AlphaMeld technology platform.
Invea Therapeutics overview
Invea Therapeutics (Invea) is a biotechnology company focuses on the discovery of therapeutics for gastrointestinal and hepatobiliary disorders. Invea is headquartered in Guilford, Connecticut,the US.
For a complete picture of INVA-8002’s drug-specific PTSR and LoA scores, buy the report here.